Similar articles

• Drug advertisements in less-developed countries.

  Dal-Pizzol F. Dal-Pizzol F. Lancet. 2002 Apr 20;359(9315):1439-40. doi: 10.1016/S0140-6736(02)08383-6. Lancet. 2002. PMID: 11978373 No abstract available.
• The important world of drug prequalification.

  [No authors listed] [No authors listed] Lancet. 2004 Nov 20-26;364(9448):1830. doi: 10.1016/S0140-6736(04)17450-3. Lancet. 2004. PMID: 15555646 No abstract available.
• New countermeasures considered as drug counterfeiting grows.

  Schubert C. Schubert C. Nat Med. 2008 Jul;14(7):700. doi: 10.1038/nm0708-700a. Nat Med. 2008. PMID: 18607355 No abstract available.
• Substandard medicines in resource-poor settings: a problem that can no longer be ignored.

  Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J. Caudron JM, et al. Trop Med Int Health. 2008 Aug;13(8):1062-72. doi: 10.1111/j.1365-3156.2008.02106.x. Epub 2008 Jul 8. Trop Med Int Health. 2008. PMID: 18631318 Review.
• Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.

  Guennif S. Guennif S. Appl Health Econ Health Policy. 2017 Oct;15(5):557-565. doi: 10.1007/s40258-017-0306-1. Appl Health Econ Health Policy. 2017. PMID: 28120166 Review.